Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. - Wikidata - awgldk - TriplyDB

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

http://www.wikidata.org/entity/Q46632481

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment New targeted treatments for non-small-cell lung cancer - role of nivolumab Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Targeting microRNAs as key modulators of tumor immune response Advances in immunotherapy for melanoma Human Cancer Immunotherapy with PD-1/PD-L1 Blockade Nivolumab in the treatment of malignant melanoma: review of the literature PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook New immunotherapies targeting the PD-1 pathway Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Targeting inhibitory pathways in cancer immunotherapy.Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets.Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis.Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue.Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity Immunotherapies: the blockade of inhibitory signals.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

P2860

Q26738359-49A39771-137B-43A1-B150-63678A398132 Q26740988-CB13FDB6-8607-41C4-9BFF-D6B688CBED9C Q26745516-591E8047-6CDC-4433-B971-A20892ED4933 Q26746972-D259767B-9C29-4FAF-8F9C-1C0C245B27FE Q26768558-73890FAA-C337-481A-9AA5-6BA2B41AAD70 Q26786108-54DE7B1A-8DCD-48B8-9498-2770ACB5F8E6 Q26798330-769E48BA-6252-42DC-8422-E3F7F22B5A3D Q26865789-32CA8AD0-F95A-4974-9EB2-D955236BA240 Q27004178-035824FE-C7B4-4365-9B03-E5E2EE299744 Q27010018-8D166A28-4245-4821-B89B-DD6DACE064F1 Q27350034-2A215585-8E10-4F28-A390-1D050D91D9A5 Q27490345-201592AF-117C-45CD-B80E-C503EDDFE7ED Q28075712-242ECE7C-74EF-40A8-916F-0A63778CF18F Q29620051-2955B525-38F5-49C3-B1CF-6C41FF797AF1 Q33710008-4C7D2516-6CAB-49FE-BD64-A510171B0BD1 Q33732329-C239B007-75BB-43AA-97BE-AEA389C02A17 Q33950640-21FCCA60-069F-4C06-B81E-76AB01838871 Q34018408-F5E77E64-0994-45C4-92AA-8ADE81FE5876 Q34018474-DB16D7ED-E3D4-4C67-B805-B6628ABB407D Q34080914-070CE3A8-B937-48DD-891C-A583BF0901BA Q34135426-2C5655D8-F2B8-475A-88DD-518DEACB938B Q34443923-EFE41E58-0D71-418D-AB48-60930E54D010 Q34538075-799F6E33-079E-449A-BD12-F8ECF1A48443 Q34548226-9DC9CE53-12E4-40F0-8209-8597D2347069 Q34561877-C6AD569B-588A-4B42-9421-E4768567101D Q34606735-E72FE883-F330-4B05-ABC3-83D056FDB95E Q34809019-9034F148-9D07-4D06-9D37-68B68044EC87 Q35167733-802764C1-3CC9-4505-ACA0-0310D96271E1 Q35176347-56136F97-44A9-4F38-A4C5-12D8BBEAD914 Q35184928-95A7AFF4-0868-4561-ACC8-28F248431FB7 Q35201893-06250C44-D1CC-44B5-96F1-AC1934C74F90 Q35586932-4442D282-2CDD-4B38-B64B-A6FB649557D1 Q35681604-EFA25537-AE0F-4EE0-9ECC-441DCF8F0B5B Q35942226-8BA0CDC3-C8E4-48ED-A96E-82E85A5C259B Q36045037-40413680-7D35-4798-9370-C74D21B166BC Q36240460-6E4E781A-0362-4807-8C86-B1ECF3BDBE9B Q36292012-557D0DC7-DDE5-4033-A44E-B903E2D2D0EA Q36431677-C2CD8920-B170-4540-B5CA-C3843CF31869 Q36512076-8A75E977-395A-452C-A4DD-1BBF78B39D22 Q36597350-6C3F87B7-A601-452D-B842-AA8C655060D9

P2860

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

http://www.wikidata.org/entity/Q46632481

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@en

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@nl

type

label

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@en

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@nl

prefLabel

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@en

Programmed death-1 blockade en ...... elanoma antigen-specific CTLs.

@nl

P1433

Q46632481-648F45A2-E5DB-420F-AED8-61EC354C3380

P1476

Q46632481-51D01DF1-2634-47AF-B54B-03748E6F118D

P2093

Q46632481-2868FCE0-B3A8-4655-99A9-E44B7A33A382

Q46632481-3A1B3578-67C1-40A5-B8A4-0D4BB0D0683E

Q46632481-48AECCCC-5CBE-4448-9EA4-E2B248865FC7

Q46632481-4A188F89-A34D-4169-85FC-B6741AD4508B

Q46632481-60F4FD73-FF83-427E-BF9C-2EB20B0FFFC7

Q46632481-FF3756D9-9025-4A06-8FDA-A334CEB83F88

P2860

Q46632481-00A9325B-19BB-4AA0-914E-82E95FC680C4

Q46632481-0663C65C-F73C-4F0D-B8BF-DFE359554CDD

Q46632481-07C2D4DC-C588-4AD8-BEEB-18AB9568F117

Q46632481-095C2EDE-F978-4A16-97B7-12E69ADFEB42

Q46632481-0BAFC21A-EA48-4D28-B611-EA8FAF21D220

Q46632481-0ED4C0D6-9BEE-4AFD-82BA-94157CC41355

Q46632481-109BF7AC-B027-4E6F-9D85-F61B06DD9906

Q46632481-2D8A9A84-FE80-4754-BF29-8AEB50DFA9B4

Q46632481-303E5FF2-F649-452D-989A-56D0AF935CEF

Q46632481-39AFA41B-3ECD-49C4-A41A-64DA5DDA81E2

P304

Q46632481-BD5008C8-847C-419A-A1FA-0DBA55DF1218

P31

Q46632481-90A99F01-D69A-4DB0-98C8-B0F0C4EB55F3

P356

Q46632481-E519B7C0-290E-4EC5-8C08-D09F20503B77

P433

Q46632481-A74E29F3-D8A8-46F2-AAD5-73A9E43A96FB

P478

Q46632481-D491C625-35C3-4C73-9BC2-71632C2065D7

P50

Q46632481-62037729-4796-4DA7-BDC4-BE9B1AFA4576

P577

Q46632481-420B7235-1FB1-4B80-85F7-DB3C10E08CE6

P5875

Q46632481-383B387B-6FC3-4561-A187-C3FFCC8FD51E

P698

Q46632481-62B20C25-1C76-4649-A0B0-439E5662B19E

P356

P1433

International Immunology

P1476

Programmed death-1 blockade en ...... melanoma antigen-specific CTLs

@en

P2093

Alan J Korman

http://www.w3.org/2001/XMLSchema#string

Changyu Wang

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Weber

http://www.w3.org/2001/XMLSchema#string

Raymond M Wong

http://www.w3.org/2001/XMLSchema#string

Ron R Scotland

http://www.w3.org/2001/XMLSchema#string

Roy L Lau

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Diversity and recognition efficiency of T cell responses to cancer

PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion

The B7 family revisited

P304

1223-1234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INTIMM/DXM091

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5946782

http://www.w3.org/2001/XMLSchema#string

P698

17898045

http://www.w3.org/2001/XMLSchema#string